• 1
    Hachulla E, Coghlan JG.A new era in the management of pulmonary arterial hypertension related to scleroderma: endothelin receptor antagonism [review].Ann Rheum Dis2004;63:100914.
  • 2
    Avouac J, Airo P, Meune C, Beretta L, Dieude P, Caramaschi P, et al.Prevalence of pulmonary hypertension in systemic sclerosis in European Caucasians and meta-analysis of 5 studies.J Rheumatol2010;37:22908.
  • 3
    Fisher MR, Mathai SC, Champion HC, Girgis RE, Housten-Harris T, Hummers L, et al.Clinical differences between idiopathic and scleroderma-related pulmonary hypertension.Arthritis Rheum2006;54:304350.
  • 4
    Tan FK.Systemic sclerosis: the susceptible host (genetics and environment) [review].Rheum Dis Clin North Am2003;29:21137.
  • 5
    Jonigk D, Golpon H, Bockmeyer CL, Maegel L, Hoeper MM, Gottlieb J, et al.Plexiform lesions in pulmonary arterial hypertension: composition, architecture, and microenvironment.Am J Pathol2011;179:16779.
  • 6
    Al Sabbagh MR, Steen VD, Zee BC, Nalesnik M, Trostle DC, Bedetti CD, et al.Pulmonary arterial histology and morphometry in systemic sclerosis: a case-control autopsy study.J Rheumatol1989;16:103842.
  • 7
    Hassoun PM, Mouthon L, Barbera JA, Eddahibi S, Flores SC, Grimminger F, et al.Inflammation, growth factors and pulmonary vascular remodeling.J Am Coll Cardiol2009;54:S109.
  • 8
    Okawa-Takatsuji M, Aotsuka S, Fujinami M, Uwatoko S, Kinoshita M, Sumiya M.Up-regulation of intercellular adhesion molecule-1 (ICAM-1), endothelial leucocyte adhesion molecule-1 (ELAM-1) and class II MHC molecules on pulmonary artery endothelial cells by antibodies against U1-ribonucleoprotein.Clin Exp Immunol1999;116:17480.
  • 9
    Lee SD, Shroyer KR, Markham NE, Cool CD, Voelkel NF, Tuder RM.Monoclonal endothelial cell proliferation is present in primary but not secondary pulmonary hypertension.J Clin Invest1998;101:92734.
  • 10
    Choi JJ, Min DJ, Cho ML, Min SY, Kim SJ, Lee SS, et al.Elevated vascular endothelial growth factor in systemic sclerosis.J Rheumatol2003;30:152933.
  • 11
    Distler O, Del Rosso A, Giacomelli R, Cipriani P, Conforti ML, Guiducci S, et al.Angiogenic and angiostatic factors in systemic sclerosis: increased levels of vascular endothelial growth factor are a feature of the earliest disease stages and are associated with the absence of fingertip ulcers.Arthritis Res2002;4:R11.
  • 12
    Dorfmuller P, Humbert M, Perros F, Sanchez O, Simonneau G, Muller KM, et al.Fibrous remodeling of the pulmonary venous system in pulmonary arterial hypertension associated with connective tissue diseases.Hum Pathol2007;38:893902.
  • 13
    Overbeek MJ, Vonk MC, Boonstra A, Voskuyl AE, Vonk-Noordegraaf A, Smit EF, et al.Pulmonary arterial hypertension in limited cutaneous systemic sclerosis: a distinctive vasculopathy.Eur Respir J2009;34:3719.
  • 14
    Tew MB, Arnett FC, Reveille JD, Tan FK.Mutations of bone morphogenetic protein receptor type II are not found in patients with pulmonary hypertension and underlying connective tissue diseases [letter].Arthritis Rheum2002;46:282930.
  • 15
    Wipff J, Kahan A, Hachulla E, Sibilia J, Cabane J, Meyer O, et al.Association between an endoglin gene polymorphism and systemic sclerosis-related pulmonary arterial hypertension.Rheumatology (Oxford)2007;46:6225.
  • 16
    Wipff J, Dieude P, Guedj M, Ruiz B, Riemekasten G, Cracowski JL, et al.Association of a KCNA5 gene polymorphism with systemic sclerosis–associated pulmonary arterial hypertension in the European Caucasian population.Arthritis Rheum2010;62:3093100.
  • 17
    Denton CP, Zheng B, Evans LA, Shi-wen X, Ong VH, Fisher I, et al.Fibroblast-specific expression of a kinase-deficient type II transforming growth factor β receptor leads to paradoxical activation of TGF β signaling pathways with fibrosis in transgenic mice.J Biol Chem2003;278:2510919.
  • 18
    Denton CP, Lindahl GE, Khan K, Shiwen X, Ong VH, Gaspar NJ, et al.Activation of key profibrotic mechanisms in transgenic fibroblasts expressing kinase-deficient type II transforming growth factor-β receptor (TβRIIΔk).J Biol Chem2005;280:1605365.
  • 19
    Taraseviciene-Stewart L, Kasahara Y, Alger L, Hirth P, McMahon G, Waltenberger J, et al.Inhibition of the VEGF receptor 2 combined with chronic hypoxia causes cell death-dependent pulmonary endothelial cell proliferation and severe pulmonary hypertension.FASEB J2001;15:42738.
  • 20
    Ciuclan L, Bonneau O, Hussey M, Duggan N, Holmes AM, Good R, et al.A novel murine model of severe pulmonary arterial hypertension.Am J Respir Crit Care Med2011;184:117182.
  • 21
    Hoyles RK, Khan K, Shiwen X, Howat SL, Lindahl GE, Leoni P, et al.Fibroblast-specific perturbation of transforming growth factor β signaling provides insight into potential pathogenic mechanisms of scleroderma-associated lung fibrosis: exaggerated response to alveolar epithelial injury in a novel mouse model.Arthritis Rheum2008;58:117588.
  • 22
    Derrett-Smith EC, Dooley A, Khan K, Shi-wen X, Abraham D, Denton CP.Systemic vasculopathy with altered vasoreactivity in a transgenic mouse model of scleroderma.Arthritis Res Ther2010;12:R69.
  • 23
    Vandesompele J, De Preter K, Pattyn F, Poppe B, Van Roy N, De Paepe A, et al.Accurate normalization of real-time quantitative RT-PCR data by geometric averaging of multiple internal control genes.Genome Biology2002;3:111.
  • 24
    Tanabe K, Tokuda H, Takai S, Matsushima-Nishiwaki R, Hanai Y, Hirade K, et al.Modulation by the steroid/thyroid hormone superfamily of TGF-β-stimulated VEGF release from vascular smooth muscle cells.J Cell Biochem2006;99:18795.
  • 25
    Mata-Greenwood E, Grobe A, Kumar S, Noskina Y, Black SM.Cyclic stretch increases VEGF expression in pulmonary arterial smooth muscle cells via TGF-β1 and reactive oxygen species: a requirement for NAD(P)H oxidase.Am J Physiol Lung Cell Mol Physiol2005;289:L28898.
  • 26
    Kobayashi T, Liu X, Wen FQ, Fang Q, Abe S, Wang XQ, et al.Smad3 mediates TGF-β1 induction of VEGF production in lung fibroblasts.Biochem Biophys Res Commun2005;327:3938.
  • 27
    Ferrari G, Terushkin V, Wolff MJ, Zhang X, Valacca C, Poggio P, et al.TGF-β1 induces endothelial cell apoptosis by shifting VEGF activation of p38MAPK from the prosurvival p38β to proapoptotic p38α.Mol Cancer Res2012;10:60514.
  • 28
    Fernandes F, Ramires FJ, Arteaga E, Ianni BM, Bonfa ES, Mady C.Cardiac remodeling in patients with systemic sclerosis with no signs or symptoms of heart failure: an endomyocardial biopsy study.J Card Fail2003;9:3117.
  • 29
    Overbeek MJ, Lankhaar JW, Westerhof N, Voskuyl AE, Boonstra A, Bronzwaer JG, et al.Right ventricular contractility in systemic sclerosis-associated and idiopathic pulmonary arterial hypertension.Eur Respir J2008;31:11606.
  • 30
    Grigoryev DN, Mathai SC, Fisher MR, Girgis RE, Zaiman AL, Housten-Harris T, et al.Identification of candidate genes in scleroderma-related pulmonary arterial hypertension.Transl Res2008;151:197207.
  • 31
    Savai R, Pullamsetti SS, Kolbe J, Bieniek E, Voswinckel R, Fink L, et al.Immune and inflammatory cell involvement in the pathology of idiopathic pulmonary arterial hypertension.Am J Respir Crit Care Med2012;186:89790.
  • 32
    Razani B, Engelman JA, Wang XB, Schubert W, Zhang XL, Marks CB, et al.Caveolin-1 null mice are viable but show evidence of hyperproliferative and vascular abnormalities.J Biol Chem2001;276:3812138.
  • 33
    Maurer B, Reich N, Juengel A, Kriegsmann J, Gay RE, Schett G, et al.Fra-2 transgenic mice as a novel model of pulmonary hypertension associated with systemic sclerosis.Ann Rheum Dis2012;71:13827.